The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

October 10, 2019

Robert L. Coleman, MD, FACOG, FACS, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of immunotherapy in patients with cervical cancer.

October 09, 2019

Michael Wang, MD, discusses the toxicity profiles of the BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib in mantle cell lymphoma.

October 05, 2019

Naoto Tada Ueno, MD, PhD, FACP, discusses the diagnosis and treatment of patients with inflammatory breast cancer and highlights the biggest challenges in both diagnosing and treating this patient population.

September 25, 2019

Michael Wang, MD, discusses data from a phase I/II study looking at the use a triplet regimen of vorinostat, cladribine, and rituximab in patients with newly diagnosed mantle cell lymphoma.

September 20, 2019

Michael Wang, MD, discusses CAR T-cell therapy and triple-resistance in mantle cell lymphoma.

September 19, 2019

Eric Jonasch, MD, on how understanding features within the tumor microenvironment and mutated epigenetic modifying genes may provide insight on prognosis or treatment strategies in renal cell carcinoma.

September 06, 2019

Michael Wang, MD, discusses resistance to CAR T-cell therapy and the next steps to overcoming this challenge in treatment for mantle cell lymphoma.

August 30, 2019

Naveen Pemmaraju, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the ongoing phase I/II trial of tagraxofusp (SL-401; Elzonris) in patients with intermediate- or high-risk relapsed/refractory myelofibrosis.

August 28, 2019

Jennifer K. Litton, MD, associate professor in the Department of Breast Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the potential advantage of using biosimilars in oncology.

August 15, 2019

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses encouraging trial findings in metastatic colorectal cancer (mCRC).

August 09, 2019

Jorge Cortes, MD, discusses frontline advances, discontinuation, and remaining challenges in the chronic myeloid leukemia paradigm.

August 06, 2019

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses the implications of the NILE trial in non–small cell lung cancer (NSCLC).

July 31, 2019

Sattva Neelapu, MD, discusses the use of CAR T-cell therapy in the third-line setting for patients with large B-cell lymphoma.

July 24, 2019

Elias Jabbour, MD, highlights the evolving armamentarium and next steps in the treatment paradigm for acute myeloid leukemia.

July 17, 2019

Michael Wang, MD, provides insight on recent advances in mantle cell lymphoma as well as research efforts for patients with a high risk of relapse.

July 16, 2019

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses the benefits of liquid biopsy compared with standard tissue in lung cancer.

July 09, 2019

Funda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics, medical director of the Institute for Personalized Cancer Therapy, and a professor in the Divisions of Cancer Medicine and Surgery at The University of Texas MD Anderson Cancer Center, discusses the activity of the combination of telaglenastat (CB-839) and cabozantinib (Cabometyx) in heavily pretreated patients with metastatic renal cell carcinoma (mRCC).

June 25, 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the pace of progress in mantle cell lymphoma (MCL).

June 25, 2019

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the mechanism of action of tisotumab vedotin (HuMax-TF-ADC) in patients with cervical cancer.

June 19, 2019

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, discusses distinguishing features of the Guardant360 assay in non–small cell lung cancer (NSCLC).